Mass. biopharma gets $60M funding boost

08/2/2013 | American City Business Journals

A Series C funding round has brought in $60 million for Dicerna Pharmaceuticals, a Watertown, Mass.-based firm developing novel treatments using its Dicer enzyme and technologies. The firm plans to use the money to take two programs into clinical development and to further develop preclinical candidates. "Over the next two years we will launch several Dicer Substrate pharmaceuticals into clinical development, targeting well-understood orphan diseases as well as classic undruggable targets in oncology," Dicerna CEO Douglas Fambrough said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ